publication date: Nov. 30, 2018

In Brief

The Pancreatic Cancer Collective awards $7 million in first-round “New Therapies Challenge” grants

The Pancreatic Cancer Collective, a strategic partnership of the Lustgarten Foundation and Stand Up To Cancer, has awarded a total of $7 million in first-round “New Therapies Challenge” grants to seven teams of cancer researchers to explore new pancreatic cancer treatments.

The announcement was made by the American Association for Cancer Research, the scientific partner of SU2C. Each team will receive up to $1 million in initial funding, with $4 million per team for clinical studies awaiting the most successful projects in the second round.

These teams are the first projects funded under the Pancreatic Cancer Collective, which was launched this spring to accelerate pancreatic cancer research and improve patient outcomes for pancreatic cancer.

The seven teams given funding in this first round of the Collective’s New Therapies Challenge will conduct their research for the next 14 months, reporting their results to the Collective and the Joint Scientific Advisory Committee which selected these teams. The second round of funding of $4 million per team will support clinical studies of the most promising teams from the first round.

The Pancreatic Cancer Collective’s New Therapies Challenge Research Teams are:

Adoptive Transfer of TGF- Resistant TIL to Defeat Immunosuppressive PDAC: Team leader: Patrick Hwu, University of Texas MD Anderson Cancer Center; co-leaders: Chantale Bernatchez, University of Texas MD Anderson Cancer Center, and Cliona Rooney, Baylor College of Medicine. The team will create tumor-specific killer T cells (tumor-infiltrating lymphocytes, or TILs) that are resistant to transforming growth factor beta (a protein that can counteract the immune system), and use the TILs to attack pancreatic cancer.

Combined … Continue reading The Pancreatic Cancer Collective awards $7 million in first-round “New Therapies Challenge” grants

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.